[Clinical effect of continuous infusion of meropenem on bacterial pneumonia in the elderly]

Area of Science:

• Infectious Diseases
• Geriatrics
• Pharmacology

Background:

• Bacterial pneumonia poses a significant threat to the elderly population.
• Optimizing antibiotic delivery methods, such as continuous infusion, may improve treatment outcomes.

Purpose of the Study:

• To evaluate the clinical and bacteriological efficacy of continuous 24-hour infusion of meropenem (MEPM) in elderly patients with bacterial pneumonia.
• To assess the safety and side effects associated with this treatment regimen.

Main Methods:

• Prospective study involving 26 elderly patients (age > 65) with moderate to severe community-acquired or hospital-acquired pneumonia.
• Continuous intravenous infusion of meropenem (1.0g/day) for 7-14 days.
• Assessment of clinical response, bacteriological eradication, and adverse events.

Main Results:

• An overall clinical efficacy rate of 88.5% (23/26 patients) was observed.
• Bacteriological efficacy was noted against susceptible strains including Klebsiella pneumoniae and Streptococcus pneumoniae.
• Meropenem was ineffective against resistant strains like MRSA and Pseudomonas aeruginosa.
• Mild laboratory abnormalities were reported in two patients.

Conclusions:

• Continuous infusion of meropenem is clinically effective for treating bacterial pneumonia in the elderly.
• The study highlights the need for comparative studies between continuous and intermittent meropenem administration strategies.